Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

Abstract Treatment‐free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation in patients with deep molecular response (DMR) is a paramount goal in the current chronic myeloid leukemia (CML) therapeutic strategy. The best DMR level by real‐time quantitative PCR (RT‐qPCR) for TKI discon...

Full description

Bibliographic Details
Main Authors: Simona Bernardi, Michele Malagola, Camilla Zanaglio, Nicola Polverelli, Elif Dereli Eke, Mariella D’Adda, Mirko Farina, Cristina Bucelli, Luigi Scaffidi, Eleonora Toffoletti, Clara Deambrogi, Fabio Stagno, Micaela Bergamaschi, Luca Franceschini, Elisabetta Abruzzese, Maria Domenica Divona, Marco Gobbi, Francesco Di Raimondo, Gianluca Gaidano, Mario Tiribelli, Massimiliano Bonifacio, Chiara Cattaneo, Alessandra Iurlo, Domenico Russo
Format: Article
Language:English
Published: Wiley 2019-05-01
Series:Cancer Medicine
Subjects:
chronic myeloid leukemia
digital PCR (dPCR)
minimal residual disease (MRD) monitoring
treatment‐free remission (TFR)
tyrosine kinase inhibitors (TKI) discontinuation
Online Access:https://doi.org/10.1002/cam4.2087

Internet

https://doi.org/10.1002/cam4.2087

Similar Items